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Abstract
Background: Our aim was to investigate the relationship between coexisting cluster headache (CH) and migraine
with anxiety and depression during active cluster bouts, and how symptoms change during remission.
Methods: We analyzed data from 222 consecutive CH patients and 99 age- and sex-matched controls using a
prospective multicenter registry. Anxiety or depression was evaluated using the Generalized Anxiety Disorder-7
(GAD-7) or Patient Health Questionnaire-9 (PHQ-9), respectively. Moderate-to-severe anxiety or depression was
defined as a score of ≥10 at baseline (during a cluster bout). We assessed for changes in anxiety and depression
during CH remission periods.
Results: Among the CH patients, the prevalence of moderate-to-severe anxiety and depression was seen in 38.2%
and 34.6%, respectively. Compared with controls, CH patients were associated with moderate-to-severe anxiety and
depression (multivariable-adjusted odds ratio [aOR] = 7.32, 95% confidence intervals [CI] = 3.35–15.99 and aOR = 4.95,
95% CI = 2.32–10.57, respectively). CH patients with migraine were significantly more likely to have moderate-to-
severe anxiety and depression (aOR = 32.53, 95% CI = 6.63–159.64 and aOR = 16.88, 95% CI = 4.16–68.38,
respectively), compared to controls without migraine. The GAD-7 and PHQ-9 scores were significantly reduced
between cluster bout and remission periods (from 6.8 ± 5.6 to 1.6 ± 2.8; P < 0.001, and from 6.1 ± 5.0 to 1.8 ± 2.4; P <
0.001, respectively).
Conclusions: Our results indicate that CH patients are at increased risk of anxiety and depression, especially in the
presence of coexisting migraine. However, the anxiety and depression can improve during remission periods.
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Introduction
Cluster headache (CH) is a rare primary headache dis-
order characterized by recurrent excruciatingly severe
unilateral pain in association with ipsilateral cranial
autonomic features [1–3]. The name cluster headache
stems from the tendency of the pain attacks to cluster
together within bouts that usually last several weeks,
which is unlike migraine and any other primary head-
ache disorder. Approximately 80–90% of CH patients
have episodic cluster headaches (ECH), where active
cluster bouts are separated by remissions lasting more
than 3months.
In primary headaches, mainly migraine, psychiatric co-
morbidities are important because they can potentially
impact the clinical course, quality of life, and headache
management negatively [4–8]. Previous studies have
shown that CH patients can have psychiatric comorbidi-
ties such as anxiety and depression [9–16]. In addition,
depressive symptoms can influence disease burden [14].
However, whether the risk of anxiety and depression dif-
fers according to the status of the cluster headaches (ac-
tive bout vs. remission) has not been investigated in
detail to date [11, 17, 18]. In addition, in a subset of CH
patients ranging from 10.0% to 16.7%, migraine has been
reported to coexist [19–22]. Given the well-recognized
link between migraine and psychiatric comorbidities,
coexisting migraine may independently influence the risk
for anxiety and depression in CH patients, although this
is a relatively unexplored area to date.
Considering the debilitating nature of repetitive CH at-
tacks during an active cluster bout, we hypothesized that
CH patients were at an increased risk for anxiety and de-
pression in active bout period, but that their anxiety and
depression would reduce during remission. In addition,
given the relationship between migraine and psychiatric
comorbidities, we further hypothesized that the risk for
anxiety and depression could be influenced by coexisting
migraine in CH patients. To test these hypotheses, we
conducted a prospective study based on data from a
multicenter CH registry to investigate the associations
between CH, coexisting migraine, anxiety, and depres-
sion during an active episode of cluster bout (acting as
the baseline period) and changes in anxiety and depres-
sion during remission periods.
Methods
Participants and study design
This cross-sectional study was planned as a part of the
Korean Cluster Headache Registry (KCHR) study, a pro-
spective, multicenter registry enrolling consecutive CH
patients aged ≥19 years at 16 hospitals across Korea - 14
university hospitals (eight tertiary and six secondary re-
ferral centers) and 2 secondary referral general hospitals.
Patient enrollment was conducted between September
2016 and December 2018 following Institutional Review
Board (IRB) approval in each hospital. For the present
study, among all the KCHR participants, we enrolled
only those with CH compatible with the third edition of
The International Classification of Headache Disorders
(ICHD-3) [23]. Comorbid migraine was also determined
based on the ICHD-3. The detailed protocol of the
KCHR has been published elsewhere previously [24–26].
The study protocol was approved by the IRB in each
study hospital and complied with the Declaration of
Helsinki and Good Clinical Practice guidelines. All pa-
tients fully understood the study aims and gave informed
written consent before their participation. Due to the na-
ture of our research question, we included patients who
enrolled during the cluster bout period of CH.
Control subjects without CH were recruited from 3
out of the 16 hospitals, and were matched on the basis
of age and sex. Volunteers aged 19–65 years were invited
to participate in this study as a control group, as long as
they had no history of diabetes, thyroid illness, severe
obesity, severe hepatic or renal illness, or malignancy,
and they had the cognitive capacity to complete the
questionnaires. Many of the control group participants
were friends or relatives of patients with headaches, or
employees of the hospital. We evaluated all of the con-
trol group participants to determine the presence of mi-
graine based on the ICHD-3. Eligibility of the rest of
controls was being headache free (< 1 headache day per
month) with no previous history of primary or secondary
headache disorder. All control subjects were enrolled
after receiving informed written consent.
Measurement
The KCHR included demographic and clinical data that
were collected during the last cluster bout. Anxiety and
depression were assessed using the Korean versions of
the Generalized Anxiety Disorder 7-item scale (GAD-7)
and the Patient Health Questionnaire 9-item scale
(PHQ-9). Each item of GAD-7 and PHQ-9 was mea-
sured on a four-point scale, from 0 to 3 (0 = never, 1 =
several days, 2 =more than half the time, and 3 = nearly
every day). Items were scored based on occurrence over
the previous 2 weeks. The total scores of GAD-7 and
PHQ-9 ranged from 0 to 21 and from 0 to 27, respect-
ively. Based these scores, the patients were classified into
three anxiety and depression severity groups: no anxiety
(GAD-7 score: 0–4), mild anxiety (GAD-7 score: 5–9),
and moderate-to-severe anxiety (GAD-7 score: 10–21),
and no depression (PHQ-9 score: 0–4), mild depression
(PHQ-9 score: 5–9), and moderate-to-severe depression
(PHQ-9 score: 10–27) [18].
Regarding the presence of anxiety, study participants
were divided dichotomously into the groups of no anx-
iety (GAD-7 score ≤ 4) or any anxiety (GAD-7 score ≥ 5)
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group. The same was done for depression, with the two
groups being a no depression group (PHQ-9 score ≤ 4)
and an any depression (PHQ-9 score ≥ 5) group. During
follow-up, CH patients were asked to repeat the tests of
GAD-7 and PHQ-9 when their cluster bout status sub-
sided into remission. Given that GAD-7 and PHQ-9
evaluate the status of anxiety and depression within the
last 2 weeks, CH patients performed the follow-up tests
of GAD-7 and PHQ-9 after 2 weeks following the end of
their cluster bout. During the remission period, we eval-
uated for a change in GAD-7 and PHQ-9 scores between
the cluster bout and the remission period. The exclusion
criteria for the remission period analysis were as follows:
[1] chronic cluster headache (CCH) [2]; no, or incom-
plete, response to the GAD-7 or PHQ-9 questionnaire
[3]; follow-up GAD-7 and PHQ-9 testing performed
within 2 weeks of the end of their cluster bout; and [4]
uncertainty as to the end date of the active cluster bout.
Statistical analysis
To test the study hypothesis, CH patients and control
subjects were classified into 4 groups according to the
presence of coexisting migraine: a CH with migraine
group, a CH without migraine group, a control group
with migraine, and a control group without migraine.
Continuous variables are presented as mean values ±
standard deviation, and categorical variables are pre-
sented as numbers (percentage). The Chi-square test for
categorical variables and the one-way ANOVA test for
continuous variables were used for the assessment of
statistical significance of intergroup differences. To iden-
tify whether CH and coexisting migraine were associated
with anxiety and depression in CH, we performed a lo-
gistic regression analysis. The results of the univariate
analyses are presented as odds ratios (ORs) accompanied
by 95% confidence intervals (CIs). To determine whether
CH and coexisting migraine were independent variables
contributing to anxiety and depression in CH, we calcu-
lated multivariable-adjusted odds ratios (aORs) and 95%
CIs after adjusting for potential covariates. To assess for
a change in anxiety and depression scores between active
cluster bout and remission periods (remission period
analysis), we used the paired t-test for the continuous
data and the McNemar test for the dichotomous groups
we created, as mentioned above. Since we expected a re-
duction in the GAD-7 and PHQ-9 scores during remis-
sion, in those with GAD-7 and/or PHQ-9 scores ≥5
during an acute cluster bout we compared the propor-
tion of participants experiencing a more than 50% re-
duction in the GAD-7 and PHQ-9 scores, according to
prespecified subgroups (age < 40 years vs. age ≥ 40 years,
male sex vs. female sex, and presence of migraine vs.
lack of migraine). All statistical analyses were performed
using SPSS for Windows Version 18.0 (SPSS Inc.,
Chicago, IL, USA). All P-values reported as < 0.05 in
two-tailed tests were considered statistically significant.
Results
Study participants, anxiety, and depression
During the study period, 222 CH patients and 99 age-
and sex-matched controls were enrolled in the multicen-
ter headache registry (Fig. 1). Baseline characteristics
between the CH patients and controls are shown in
Table 1. No significant differences were observed across
the groups of the CH patients and controls in terms of
age, sex, current smoking status, and alcohol consump-
tion status. With respect to the CH subtype, of the 222
CH patients, 157 (70.7%), 11 (4.9%), and 24 (10.8%) pa-
tients were classified as having ECH (code 3.1.1), CCH
(code 3.1.2), and probable CH (code 3.5.1), respectively. For
the remaining 33 patients (14.8%), their first episode of CH
did not turn into remission within 1 year of their onset or
did not follow more than 1 year, so they were classified nei-
ther ECH nor CCH, their diagnosis was finally coded as 3.1.
Among the CH patients, the prevalence of anxiety and
depression was 67.5% and 59.5%, respectively. The pro-
portion of CH patients with moderate-to-severe anxiety
was more than three times that seen in controls (38.2% vs.
10.1%), and the proportion of CH patients with depression
was more than double that of controls (34.6% vs. 12.1%).
The prevalence of moderate-to-severe anxiety and depres-
sion was highest in the CH with migraine group (51.6%
and 45.2%, respectively) relative to the CH without mi-
graine group and the two control groups (with and with-
out migraine). Regarding item of suicidal idea in PHQ-9,
the CH patients reported any suicidal idea (≥Several
days, item score ≥ 1) more frequently, in comparison
with the controls (26.1% vs. 10.1%; P < 0.001).
Association of cluster headache and coexisting migraine
with anxiety
In univariable analyses, the CH patients were signifi-
cantly more likely to experience any anxiety and
moderate-to-severe anxiety compared to controls
(Table 2). Those with coexisting CH and migraine had
the highest OR for moderate-to-severe anxiety (OR = 32.53,
95% CI = 6.73–157.12).
In multivariable analyses, the association between the
presence of CH, any anxiety, and moderate-to-severe
anxiety remained significant after adjustment for poten-
tial covariates. Furthermore, the association between the
control with migraine group, the CH without migraine
group, and the CH with migraine group and both any
anxiety and moderate-to-severe anxiety persisted after
multivariable adjustment. The CH with migraine group
was associated with an extremely high likelihood of
moderate-to-severe anxiety (aOR = 32.53, 95% CI =
6.63–159.64).
Kim et al. The Journal of Headache and Pain           (2020) 21:58 Page 3 of 10
Table 1 Baseline characteristics between cluster headache patients and controls
Control CH
Without migraine With migraine Without migraine With migraine
Variable (n = 63) (n = 36) (n = 191) (n = 31) P
Age, years 37.6 ± 10.2 34.8 ± 7.4 38.3 ± 11.1 37.2 ± 8.1 0.312
Female sex, n (%) 11 (17.5) 6 (16.7) 26 (13.6) 9 (29.0) 0.188
Current smoking, n (%) 20 (31.7) 13 (36.1) 89 (46.6) 7 (22.6) 0.025
Alcohol drinking, n (%) 42 (66.7) 15 (41.7) 98 (51.3) 10 (32.3) 0.008
GAD-7 score 2.7 ± 3.0 6.2 ± 4.6 7.7 ± 5.5 9.7 ± 6.9 < 0.001
Anxiety, n (%) < 0.001
None/minimal (GAD-7: 0–4) 50 (79.4) 15 (41.7) 63 (33.0) 9 (29.0)
Mild (GAD-7: 5–9) 11 (17.5) 13 (36.1) 59 (30.9) 6 (19.4)
Moderate-to-severe (GAD-7 ≥ 10) 2 (3.2) 8 (22.2) 69 (36.1) 16 (51.6)
PHQ-9 score 3.1 ± 3.1 6.6 ± 5.2 7.4 ± 6.1 9.4 ± 7.7 < 0.001
Depression, n (%) < 0.001
None/minimal (PHQ-9: 0–4) 48 (76.2) 17 (47.2) 77 (40.3) 13 (41.9)
Mild (PHQ-9: 5–9) 12 (19.0) 10 (27.8) 51 (26.7) 4 (12.9)
Moderate-to-severe (PHQ-9 ≥ 10) 3 (4.8) 9 (25.0) 63 (33.0) 14 (45.2)
The data are shown as the mean ± standard deviation or number (percentage)
Abbreviations: CH Cluster headache; GAD-7 Generalized Anxiety Disorder (7-item scale); PHQ-9 Patient Health Questionnaire (9-item scale)
Fig. 1 Flowchart for recruitment
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Association of cluster headache and coexisting migraine
with depression
In univariable analyses, the presence of CH was sig-
nificantly associated with any depression and
moderate-to-severe depression (Table 3). The CH
with migraine group had the highest OR for the pres-
ence of moderate-to-severe depression (OR = 16.47,
95% CI = 4.23–64.06).
In multivariable analyses, the presence of CH had
significant associations with any depression and
moderate-to-severe depression after adjustment for
potential covariates. Using the control without mi-
graine group as a reference, the risk of moderate-to-
severe depression was the highest in the group of
patients with coexisting CH and migraine (aOR =
16.88, 95% CI = 4.16–68.38). Regarding CH and co-
existing migraine, the CH patients with migraine had
the biggest odds for suicidal idea of ≥Several days
(OR: 8.79, 95% CI: 2.49–30.99; Supplementary Table).
Change of anxiety and depression between cluster bout
and remission periods
Following the predefined exclusion criteria, data on 52
eligible CH patients were finally analyzed in the remis-
sion period analysis (Fig. 1). The 52 patients were
followed for a median of 87.5 days (interquartile range:
42–131 days) between cluster bout and remission pe-
riods. The baseline characteristics of age, female sex,
current smoking status, alcohol consumption status,
coexisting migraine history, and the GAD-7 and PHQ-9
scores in this group did not significantly differ from
those of the other 170 patients excluded from the remis-
sion period analysis.
The mean GAD-7 and PHQ-9 scores reduced signifi-
cantly between the cluster bout and remission periods
(from 6.8 ± 5.6 to 1.6 ± 2.8; P < 0.001, and from 6.1 ± 5.0
to 1.8 ± 2.4; P < 0.001, respectively; Fig. 2). During the
remission period the prevalence of moderate-to-severe
anxiety and depression was significantly decreased.
Table 2 Association of cluster headache and coexisting migraine with anxiety
Any anxiety (GAD-7 scores ≥5) Moderate-to-severe anxiety (GAD-7 scores ≥10)
Crude OR (95% CI) P aOR (95% CI) P Crude OR (95% CI) P aOR (95% CI) P
Presence of CHa
Control reference reference reference reference
CH 3.98 (2.41–6.57) < 0.001 5.17 (2.93–9.12) < 0.001 5.52 (2.72–11.20) < 0.001 7.32 (3.35–15.99) < 0.001
Category of CH and migraineb
Control without migraine reference reference reference reference
Control with migraine 5.38 (2.18–13.25) < 0.001 5.29 (2.10–13.29) < 0.001 8.71 (1.73–43.71) 0.009 8.43 (1.65–42.96) 0.01
CH without migraine 7.81 (3.95–15.43) < 0.001 7.71 (3.84–15.49) < 0.001 17.25 (4.09–72.73) < 0.001 16.01 (3.77–68.03) < 0.001
CH with migraine 9.40 (3.50–25.22) 0.001 9.78 (3.55–26.92) 0.001 32.53 (6.73–157.12) < 0.001 32.53 (6.63–159.64) < 0.001
aAdjustment for age, female sex, current smoking, alcohol drinking, and coexisting migraine
bAdjustment for age, female sex, current smoking, and alcohol drinking
Abbreviations: aOR Multivariable-adjusted odds ratio; CH Cluster headache; CI Confidence interval; GAD-7 Generalized Anxiety Disorder (7-item scale); OR
Odds ratio
Table 3 Association of cluster headache and coexisting migraine with depression
Any depression (PHQ-9 scores ≥5) Moderate-to-severe depression (PHQ-9 scores ≥10)
Crude OR (95% CI) P aOR (95% CI) P Crude OR (95% CI) P aOR (95% CI) P
Presence of CHa
Control reference reference reference reference
CH 2.80 (1.71–4.59) < 0.001 2.95 (1.72–5.07) < 0.001 3.85 (1.98–7.47) < 0.001 4.95 (2.32–10.57) < 0.001
Category of CH and migraineb
Control without migraine reference reference reference reference
Control with migraine 3.57 (1.49–8.57) 0.004 3.24 (1.31–8.05) 0.011 6.66 (1.67–26.58) 0.007 6.07 (1.45–25.31) 0.013
CH without migraine 4.73 (2.47–9.05) < 0.001 4.20 (2.16–8.18) < 0.001 9.84 (2.97–32.62) < 0.001 8.63 (2.55–29.18) 0.001
CH with migraine 4.43 (1.76–11.11) 0.002 4.07 (1.58–10.52) 0.004 16.47 (4.23–64.06) < 0.001 16.88 (4.16–68.38) < 0.001
aAdjustment for age, female sex, current smoking, alcohol drinking, and coexisting migraine
bAdjustment for age, female sex, current smoking, and alcohol drinking
Abbreviations: aOR Multivariable-adjusted odds ratio; CH Cluster headache; CI Confidence interval; OR Odds ratio; PHQ-9 Patient Health Questionnaire
(9-item scale)
Kim et al. The Journal of Headache and Pain           (2020) 21:58 Page 5 of 10
The proportions of patients with a more than 50% re-
duction in GAD-7 and PHQ-9 scores during the remis-
sion period were analyzed according to prespecified
subgroups (Fig. 3). The proportion of patients with a
more than 50% reduction in GAD-7 and PHQ-9 scores
was greater in patients without migraine than those with
migraine (anxiety: 89.7% vs. 75.0%, and depression:
85.2% vs. 50.0%, respectively); however, the difference
did not reach statistical significance.
Discussion
In the present study, we assessed for an association be-
tween CH and coexisting migraine with anxiety and de-
pression, and for any changes between cluster bouts and
remission periods. Compared to the control group, the
CH patients were significantly more likely to have co-
morbid anxiety and depression after the multivariable
adjustment including coexisting migraine. The associa-
tions differed according to the presence of coexisting
migraine. Those in the CH with migraine group were at
high risk of having moderate-to-severe anxiety and de-
pression. In the remission period following a cluster
bout the GAD-7 and PHQ-9 scores were significantly re-
duced, suggesting that anxiety and depression improve
during the CH remission period.
Several early studies showed a wide range in the preva-
lence of psychiatric comorbidities in CH. The estimated
prevalence of anxiety and depression ranged from 11.8%
to 75.7% and 6.3% to 43.0%, respectively [9]. These re-
sults are insufficient to conclude that CH patients are at
an increased risk for having psychiatric comorbidities.
Meanwhile, a Taiwanese population study demonstrated
that in CH patients without a history of psychiatric dis-
orders, the risk for developing depression was 5.6 times
higher than in control subjects [27]. Similarly, a large-
scale US study analyzing five-year insurance claims data
demonstrated that CH patients, had 2.5 and 2.2 times
higher odds of anxiety and depression compared to
Fig. 2 a Changes in anxiety and depression scores between active cluster bouts and remission periods. b Changes in the proportion of patients
with moderate-to-severe anxiety and depression between active cluster bouts and remission periods. Abbreviations: GAD-7, Generalized Anxiety
Disorder (7-item scale); PHQ-9, Patient Health Questionnaire (9-item scale)
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controls, respectively [12]. In addition, a Dutch cross-
sectional study involving 462 CH patients and 177 con-
trols showed that CH patients had nearly double the
anxiety and depression scores of control subjects [11]. In
line with these findings, the current study can corrobo-
rate the notion that there is an increased risk of
psychiatric comorbidities in CH patients.
In the present study, it is noteworthy that the CH with
migraine group had approximately two-fold higher odds
of moderate-to-severe anxiety and depression when
compared to the CH without migraine group. This indi-
cates that the bidirectional relationship between mi-
graine and psychiatric comorbidities may further
increase the risk of anxiety and depression among CH
patients during a cluster bout. Given the debilitating na-
ture of CH, comorbid migraine often comes second
place in terms of priority, and receives little or no atten-
tion in the clinical management of CH patients during
the active cluster bout period. In this context, our find-
ings imply that clinicians should not underestimate the
presence and importance of coexisting migraine in the
comprehensive and holistic management of CH that
incorporates psychiatric well-being.
Despite the strong association between CH, anxiety,
and depression during active cluster bouts, anxiety
and depression improved remarkably at remission in
the present analysis. This suggests that the cyclical
nature of CH also applies to the psychiatric comor-
bidities experienced in CH patients. Prior to our
current research, few previous studies had examined
this important issue. A German cross-sectional study
showed that the proportion of patients with anxiety
and depression was higher for patients with ECH at
remission than those with ECH during an acute CH
episode, which goes against our expectation [17]. A
US pilot study conducted a cross-sectional compari-
son of the levels of anxiety and depression among
ECH patients between active cluster bouts and remis-
sion periods [18]. The levels of anxiety and depres-
sion were similar irrespective of CH status. Like our
Fig. 3 Proportions of patients with a more than 50% reduction in anxiety and depression according to prespecified subgroups. Abbreviations:
GAD-7, Generalized Anxiety Disorder (7-item scale); PHQ-9, Patient Health Questionnaire (9-item scale)
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study, a Dutch study found a strong association be-
tween active cluster bout and current depression [11].
However, the association was ultimately attenuated in
the final model after adjusting for the scores of sleep
disorders. Unlike those studies, our study has an ad-
vantage that the findings derive from a prospective
observation of the temporal change of anxiety and
depression.
We evaluated greater than 50% reductions in the anx-
iety and depression scale scores according to several pre-
specified subgroups. Our presumption was that anxiety
and depression in female, older patients with coexisting
migraine were less likely to improve during the remis-
sion period. We observed no significant difference in the
subgroup analysis; however, it is interesting to note that
the difference in the proportion of patients with more
than a 50% reduction in the anxiety and depression
scales during remission was greatest between the sub-
groups of patients with coexisting migraine. This sug-
gests that coexisting migraine has an important
influence on the psychological burden of CH patients,
and further studies of statistically sufficient sample size
are needed to verify this.
Several hypotheses have been already proposed with
regard to the risk of affective disorders in CH patients:
1) neuroimaging findings have shown shared anatomical
substrates for the pain matrix and depression processing;
2) similarities between CH and depression have been ob-
served in terms of hypothalamic dysfunction and
chronobiology; and 3) common mood changes are re-
ported in the pre- and post-ictal phases of a CH attack
[11, 28–32]. The possible mechanism underlying the im-
provement in anxiety and depression during remission
periods has not been specifically addressed in the litera-
ture to date. Nevertheless, there are some possible expla-
nations. First of all, the termination of the CH attack
associated with remission may in itself directly improve
the mood of CH patients, under the assumption that
mood changes during the pre- and post-ictal phases of a
CH attack contribute to the presence of anxiety and de-
pression [32]. Next, nocturnal CH attacks are common
during an active cluster bout, which can lead to sleep
disturbance as well as depression [11, 21, 31]. In light of
this, the lack of nocturnal CH attacks during the remis-
sion period may be another reason that improvement in
mood is observed. Lastly, neuroimaging studies of CH
have reported functional changes in multiple brain net-
works in relation to cluster bout status [28]. Given the
shared anatomical location of the pain matrix and de-
pression processing site, mood improvements may be a
consequence of brain changes between active cluster
bouts and remission periods.
The present study has several methodological limi-
tations. First, despite the multicenter recruitment of
study patients, our results were based on an analysis
of data from a hospital-based dataset. In particular,
the number of coexisting migraine in the CH patients
was resultantly small and similar to the migraine
prevalence of general population. Therefore, the find-
ings in the current study require confirmation
through additional population-based studies. Second,
we estimated the risk of anxiety and depression in
CH and coexisting migraine during active cluster
bouts based on a cross-sectional analysis. Third, the
median follow-up time interval used to assess for a
change in anxiety and depression between active clus-
ter bouts and remission was around 3 months. This
may be considered short, given that the duration of
the remission period varies from months to years.
Longer observational studies are required to confirm
the presence of dynamic changes in anxiety and de-
pression across repeated phases of active cluster bouts
and remission periods. Fourth, the multivariable-
adjusted logistic regression analyses to assess the as-
sociation of CH with anxiety and depression did not
adjust for unmeasured potential confounders, such as
socioeconomic status, educational level, sleep disor-
ders, more specific physical illness including low back
pain, diabetes, and other headache disorders. Further
studies complementing this weakness are required to
better verify a specific association between CH, coex-
isting migraine, anxiety, and depression. Fifth, we
used the tests of GAD-7 and PHQ-9 to investigate
the associations between CH, anxiety, and depression.
However, these tests do not confirm the diagnosis of
anxiety and depression, but only represent their state,
which should be kept in mind. Sixth, due to the mod-
erate sample size of our study, there was a small
number of the group of CH and coexisting migraine
having anxiety and depression. This may raise a prob-
lem throughout the statistical process. In this regard,
the results should be interpreted with caution. Finally,
the 10.5% patients had probable CH, which might
influence the results.
Conclusions
We have quantified the risk of anxiety and depression in
CH and coexisting migraine during active cluster bouts.
We have shown that coexisting migraine is a significant
influencer on psychiatric comorbidities in patients with
CH. Furthermore, anxiety and depression are dynamic-
ally altered between active cluster bout and remission
periods, suggesting that psychiatric comorbidities may
be cyclical in a similar manner to the cluster bouts ob-
served in CH. Further clinical and neuroimaging studies
are required to elucidate on the possible mechanisms
underlying our findings.
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